Jessica Afable
Internal Medicine · Palm Springs, CANPI 1487648929
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $984 and has fallen 71.4% since, to $282 in 2025.
Across 128 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$314
- Boehringer Ingelheim$251
- Johnson & Johnson$212
- Pfizer$169
- Gilead$156
- AbbVie$147
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,454100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $314 |
| Boehringer Ingelheim | 12 | $251 |
| Johnson & Johnson(2 entities) | 12 | $212 |
| Pfizer | 8 | $169 |
| Gilead | 7 | $156 |
| AbbVie(2 entities) | 8 | $147 |
| Novo Nordisk | 8 | $143 |
| Novartis | 8 | $137 |
| Amgen | 6 | $137 |
| AstraZeneca | 7 | $97 |
| Lilly USA, LLC | 4 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Phathom Pharmaceuticals, Inc. | 3 | $70 |
| Idorsia Pharmaceuticals US Inc | 3 | $57 |
| Merck | 3 | $54 |
| Viiv Healthcare Company | 3 | $47 |
| Astellas Pharma US Inc | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Dynavax Technologies Corporation | 1 | $24 |
| Bayer | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Sanofi | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$2,454 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $153,108 |
| OzempicSemaglutide | 108 | $125,269 |
| Breo ElliptaFluticasone/Vilanterol | 87 | $59,434 |
| JardianceEmpagliflozin | 40 | $56,300 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $54,856 |
| LinzessLinaclotide | 41 | $42,892 |
| MounjaroTirzepatide | 30 | $37,844 |
| CreonLipase/Protease/Amylase | 19 | $36,423 |
| FarxigaDapagliflozin Propanediol | 26 | $33,197 |
| JanuviaSitagliptin Phosphate | 34 | $27,176 |
| TrulicityDulaglutide | 26 | $27,058 |
| XareltoRivaroxaban | 15 | $21,710 |
| MyrbetriqMirabegron | 22 | $20,889 |
| Spiriva RespimatTiotropium Bromide | 16 | $15,392 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $13,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $169 | $153,108128 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $314 | $128,139161 claims |
| Novo NordiskOzempic | $143 | $125,269108 claims |
| AbbVieLinzess, Creon | $147 | $79,31460 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $251 | $71,69256 claims |
| Lilly USA, LLCMounjaro, Trulicity | $83 | $64,90256 claims |
| AstraZenecaFarxiga, Symbicort | $97 | $37,33737 claims |
| MerckJanuvia | $54 | $27,17634 claims |
| Johnson & JohnsonXarelto | $212 | $21,71015 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $20,88922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Palm Springs
- Jorge RodriguezPalm Springs$246K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.